B. Riley Financial Forecasts Strong Price Appreciation for Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics (NASDAQ:CAPR) had its price target hoisted by equities researchers at B. Riley Financial from $50.00 to $63.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley Financial’s target price points to a potential upside of 106.56% from the company’s previous close.

CAPR has been the subject of a number of other research reports. Maxim Group upped their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Oppenheimer boosted their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, December 8th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Piper Sandler restated an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday. Finally, Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.09.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $30.50 on Friday. The stock’s fifty day moving average is $25.70 and its two-hundred day moving average is $16.59. The firm has a market capitalization of $1.69 billion, a P/E ratio of -13.50 and a beta of 0.37. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, sell-side analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CAPR. Goldman Sachs Group Inc. boosted its stake in Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after buying an additional 116,373 shares during the period. Geode Capital Management LLC increased its position in shares of Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after acquiring an additional 61,701 shares during the last quarter. Citizens Financial Group Inc. RI raised its stake in shares of Capricor Therapeutics by 249.2% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock valued at $348,000 after acquiring an additional 24,977 shares during the period. Legal & General Group Plc lifted its holdings in shares of Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 3,205 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 3,636 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review resumed and a new PDUFA/decision date was set for Deramiocel — a major regulatory catalyst that can materially re‑rate the stock if approval looks likely. Capricor: Moving To ‘Buy’ Rating As New PDUFA Date Is Set For Deramiocel
• Positive Sentiment: Late‑breaking HOPE‑3 Phase 3 data presented at the MDA conference showed significant functional benefits for Deramiocel in DMD, supporting the therapy’s efficacy profile heading into the review. HOPE‑3 Data Release
• Positive Sentiment: Company financial positioning: Capricor highlights roughly $318M cash on hand and frames the FDA milestone as supporting potential commercialization, which reduces near‑term dilution risk. Cash & Commercialization Note
• Positive Sentiment: Analyst support has increased: B. Riley raised its price target to $63 (buy), Piper Sandler reaffirmed overweight and lifted its target to $58, and HC Wainwright reiterated buy — these upgrades boost conviction among buy‑side investors. Benzinga Coverage (B. Riley / Piper Sandler) HC Wainwright Reiterate
• Neutral Sentiment: Management tone is bullish on the regulatory path (CEO pushed back against the idea of only a conditional approval), which supports investor confidence but is not definitive on outcome. CEO Comment
• Negative Sentiment: Q4 results disappointed: EPS of ($0.62) missed consensus (~$0.51) and the loss widened year‑over‑year, prompting intraday selling and headlines calling out the miss. That weakens near‑term sentiment despite the regulatory upside. Q4 Earnings Miss Benzinga: Stock Slides

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.